Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | GRM2 | Q14416 | 4/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL378660 | 0.78 | POLB (0.50) | MAPK1POLBATMMAPTLMNA | |
| SCHEMBL3282850 | 0.76 | GRM2 (0.50) | MAPK1POLBATMMAPTLMNA | |
| Water SCHEMBL3673310 | 0.76 | POLB (0.48) | MAPK1POLBATMMAPTLMNA | |
| SCHEMBL28812584 | 0.76 | GRM2 (0.50) | MAPK1POLBATMMAPTLMNA | |
| SCHEMBL19848410 | 0.76 | SLC9A1 (0.48) | POLBMAPTLMNAGRM2KDM4E | |
| SCHEMBL16600359 | 0.74 | GAA (0.39) | MAPTDGAT1KDM4E | |
| SCHEMBL7046048 | 0.73 | MAPK1 (0.46) | MAPK1POLBATMMAPTLMNA | |
| SCHEMBL8908200 | 0.73 | MAPK1 (0.46) | MAPK1POLBATMMAPTLMNA | |
| SCHEMBL28854710 | 0.73 | POLB (0.46) | MAPK1POLBATMMAPTLMNA | |
| SCHEMBL724308 | 0.72 | MAPK1 (0.51) | MAPK1POLBATMMAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3313521-A1 | ANTIBODY DRUG CONJUGATES OF KINESIN SPINDEL PROTEIN (KSP) INHIBITORS WITH ANTI-TWEAKR-ANTIBODIES | Bayer Pharma Aktiengesellschaft (DE) | 2018-05-02 | — | — | EP | disclosed |
| EP-3313524-A1 | ANTIBODY DRUG CONJUGATES OF KINESIN SPINDEL PROTEIN (KSP) INHIBITORS WITH ANTI-CD123-ANTIBODIES | Bayer Pharma Aktiengesellschaft (DE) | 2018-05-02 | — | — | EP | disclosed |
| WO-2016207098-A1 | ANTIBODY DRUG CONJUGATES OF KINESIN SPINDEL PROTEIN (KSP) INHIBITORS WITH ANTI-CD123-ANTIBODIES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-12-29 | — | — | WO | disclosed |
| WO-2016207094-A1 | ANTIBODY DRUG CONJUGATES OF KINESIN SPINDEL PROTEIN (KSP) INHIBITORS WITH ANTI-TWEAKR-ANTIBODIES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-12-29 | — | — | WO | disclosed |
| US-9233951-B2 | Heterocyclic compounds as pesticides | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-01-12 | — | — | US | disclosed |
| US-20120094837-A1 | Novel Heterocyclic Compounds as Pesticides | BAYER CROP SCIENCE AG (DE) | 2012-04-19 | — | — | US | disclosed |
| US-20080076719-A1 | IMMUNOREGULATORY COMPOSITIONS | ERASMUS UNIVERSITEIT ROTTERDAM (NL) | 2008-03-27 | — | — | US | disclosed |
| US-7332524-B2 | Adamantyl acetamides as 11-beta hydroxysteroid dehydrogenase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-02-19 | — | — | US | disclosed |
| EP-1874933-A2 | PRODUCTION OF RECOMBINANT PROTEINS BY AUTOPROTEOLYTIC CLEAVAGE OF A FUSION PROTEIN | Sandoz AG (CH) | 2008-01-09 | — | — | EP | disclosed |
| WO-2006113959-A2 | PRODUCTION OF RECOMBINANT PROTEINS BY AUTOPROTEOLYTIC CLEAVAGE OF A FUSION PROTEIN | SANDOZ AG (CH) | 2006-11-02 | — | — | WO | disclosed |
| US-20060079506-A1 | Adamantyl acetamides as 11-beta hydroxysteroid dehydrogenase inhibitors | JANSSEN PHARMACEUTICAL N.V. (BE) | 2006-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079506-A1 | Adamantyl acetamides as 11-beta hydroxysteroid dehydrogenase inhibitors | DHCR7, HSD3B2, HSD3B1 | MAPK1 3322/4885POLB 2406/4885ATM 4789/4885 |
| US-20120094837-A1 | Novel Heterocyclic Compounds as Pesticides | DDT, PTMS, ACHE | MAPK1 4028/4885POLB 4661/4885ATM 3908/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.